The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqselvi (deuruxolitinib), made by Sun Pharma UK, as a treatment for severe alopecia areata in adults. Alopecia areata is a ...

Thousands of adults suffering from severe hair loss could soon regrow their hair thanks to a new pill approved for use in Britain. The UK’s medicines watchdog, the MHRA, has given the green light to ...

Researchers at MIT, Brigham and Women's Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects ...

TORONTO, Jan. 14, 2026 /CNW/ - Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant ® for severe alopecia areata to its public drug ...

GPT-4o achieved ICC/CCC of 0.815/0.866 versus in-person SALT scoring and 0.833/0.817 versus image-based scoring, while expert ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ritlecitinib, an oral JAK 3 inhibitor, was effective for ...

Patients with new-onset alopecia areata are at increased 10-year risk of developing several immune-mediated inflammatory diseases, according to a study.

Alopecia Areata is a common autoimmune condition in which the immune system mistakenly attacks and targets hair follicles. It can lead to sudden hair loss in the scalp, the face, even the eyebrows, ...

Janus kinase (JAK) inhibitors are associated with more hair regrowth than placebo for patients with alopecia areata, according to a review published online June 27 in JAMA Network Open. The U.S. Food ...